The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers
Active 1
  • Taslaq, Samer, Dr
    Doctor born in May 1980
    Individual (18 offsprings)
    Officer
    2020-12-16 ~ now
    OF - director → CIF 0
    Dr Samer Taslaq
    Born in May 1980
    Individual (18 offsprings)
    Person with significant control
    2020-12-08 ~ now
    PE - Ownership of shares – More than 25% but not more than 50%CIF 0
    PE - Ownership of voting rights - More than 25% but not more than 50%CIF 0
Ceased 2
  • 1
    Watson, Paul
    Director born in May 1972
    Individual (67 offsprings)
    Officer
    2018-10-23 ~ 2023-05-15
    OF - director → CIF 0
  • 2
    Leslie Anderson
    Born in September 1962
    Individual
    Person with significant control
    2018-10-23 ~ 2020-12-08
    PE - Ownership of shares – 75% or moreCIF 0
    PE - Ownership of voting rights - 75% or moreCIF 0
    PE - Right to appoint or remove directorsCIF 0
parent relation
Company in focus

SUNDARA PHARMACEUTICALS LTD

Standard Industrial Classification
72110 - Research And Experimental Development On Biotechnology
Brief company account
Intangible Assets
45,000 GBP2023-12-31
0 GBP2022-12-31
Debtors
9,045 GBP2023-12-31
41 GBP2022-12-31
Cash at bank and in hand
18,945 GBP2023-12-31
59,990 GBP2022-12-31
Current Assets
27,990 GBP2023-12-31
60,031 GBP2022-12-31
Creditors
Current, Amounts falling due within one year
-28,651 GBP2023-12-31
-2,964 GBP2022-12-31
Net Current Assets/Liabilities
-661 GBP2023-12-31
57,067 GBP2022-12-31
Total Assets Less Current Liabilities
44,339 GBP2023-12-31
57,067 GBP2022-12-31
Equity
Called up share capital
83 GBP2023-12-31
83 GBP2022-12-31
Share premium
99,943 GBP2023-12-31
99,943 GBP2022-12-31
Retained earnings (accumulated losses)
-55,687 GBP2023-12-31
-42,959 GBP2022-12-31
Equity
44,339 GBP2023-12-31
57,067 GBP2022-12-31
Average Number of Employees
22023-01-01 ~ 2023-12-31
22022-01-01 ~ 2022-12-31
Intangible Assets - Gross Cost
Other than goodwill
45,000 GBP2023-12-31
0 GBP2022-12-31
Intangible Assets - Accumulated Amortisation & Impairment
Other than goodwill
0 GBP2022-12-31
Intangible Assets
Other than goodwill
45,000 GBP2023-12-31
0 GBP2022-12-31
Other Debtors
Amounts falling due within one year
9,045 GBP2023-12-31
41 GBP2022-12-31
Trade Creditors/Trade Payables
Current
24,000 GBP2023-12-31
212 GBP2022-12-31
Other Taxation & Social Security Payable
Current
600 GBP2023-12-31
200 GBP2022-12-31
Other Creditors
Current
4,051 GBP2023-12-31
2,552 GBP2022-12-31
Creditors
Current
28,651 GBP2023-12-31
2,964 GBP2022-12-31

  • SUNDARA PHARMACEUTICALS LTD
    Info
    Registered number 11636445
    C/o Rmt Accountants & Business Advisors Ltd, Gosforth Park Avenue, Newcastle Upon Tyne NE12 8EG
    Private Limited Company incorporated on 2018-10-23 (6 years 7 months). The company status is Active.
    The last date of confirmation statement was made at 2024-10-14
    CIF 0
child relation
Offspring entities and appointments
Active 0
  • Not found in our database.
© 2022-2025 Polylogarithmic Technology Ltd. All rights reserved.
Contains public sector information retrieved at 24 April 2025 and licensed under the Open Government Licence v3.0.